ClinicaliQ Trial Snapshot
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma — Active Not Recruiting • Phase II • Oncology • NCT05909904.
- Trial testing whether adding experimental drugs to tislelizumab improves outcomes in advanced head and neck cancer patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer Interventions: Tislelizumab, BGB-A425, LBL-007 Lead Sponsor: BeiGene Planned Enrollment: 160 participants